MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

PAC-1

CAS No. : 315183-21-2

MCE 站：PAC-1

产品活性：PAC-1 是一种 procaspase-3 激活剂，诱导癌细胞凋亡，EC₅₀ 为 2.08 μM。

研究领域：Apoptosis  |  Autophagy

作用靶点：Caspase  |  Autophagy  |  Apoptosis

In Vitro: PAC-1 activates procaspase-3 with an EC₅₀ of 2.08 μM. PAC-1 exhibits an enhanced zinc chelating ability (EC₅₀= 7.08 μM). PAC-1 induces leukemia cell death with IC₅₀ of 4.03 μM, which is consistent with the values reported by other investigators. PAC-1 treatment also results in death of other malignant cells in a concentration-dependent manner with IC₅₀s ranging from 4.03 to 53.44μM. The overall mean IC₅₀ in the fifteen malignant cell lines is 0.88 mM for WF-210 ａnd 19.40 μM for PAC-1. In contrast, the sensitivity of the normal human cells (PBL, L-02, HUVEC ａnd MCF 10A) to WF-210 is 2.6-fold lower (mean IC₅₀=412.34 μM) than PAC-1 (mean IC₅₀=158.29 μM). Procaspase-activating compound-1 (PAC-1) is the first direct caspase-activating compound discovered. PAC-1 treatment upregulates Ero1α in multiple cell lines, whereas silencing of Ero1α significantly inhibits calcium release from ER ａnd cell death.

In Vivo: To evaluate the in vivo effect of WF-210 on the growth of malignant tumors, we examined the ability of WF-210 to suppress tumor growth in mouse Hep3B ａnd MDA-MB-435 xenograft models. These two cell lines express procaspase-3 at relatively high levels. Tumors induced by xenografts of the liver cancer cell Hep3B are allowed to develop ａnd grow to a size of 100 mm³, after which WF-210 (2.5 mg/kg) or PAC-1 (5.0 mg/kg) is given daily for two weeks by intravenous (i.v.) administration. As shown in both PAC-1 ａnd WF-210 significantly inhibits the growth of Hep3B tumor xenografts.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Pyroptosis Compound Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Y-27632 dihydrochloride  |  Paclitaxel  |  Acetylcysteine  |  Angiotensin II human  |  Staurosporine  |  Z-VAD-FMK  |  Bortezomib  |  5-Fluorouracil  |  Sorafenib  |  Tamoxifen  |  SP600125  |  Trametinib  |  2-Deoxy-D-glucose  |  Gemcitabine  |  Temozolomide  |  MK-2206 dihydrochloride  |  Verteporfin  |  Decitabine  |  Actinomycin D  |  Etoposide  |  Pexidartinib  |  BAY 11-7082  |  CCCP  |  DAPT

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。